menu search

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...

October 11, 2021, 12:30 pm

I-80 gold outlines details of financing package for nevada acquisitions

i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...

October 11, 2021, 8:38 am

I-80 gold outlines details of financing package for nevada acquisitions

i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...

October 11, 2021, 8:38 am

I-80 gold outlines details of financing package for nevada acquisitions

i-80 Gold Corp. said it will ask shareholders to approve the issue of common shares and other securitie...

October 11, 2021, 8:38 am

Davita climate action goals approved by the science based target initiative

DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...

October 11, 2021, 6:02 am

Davita climate action goals approved by the science based target initiative

DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...

October 11, 2021, 6:02 am

Davita climate action goals approved by the science based target initiative

DENVER, Oct. 11, 2021 /PRNewswire/ -- DaVita furthers commitment to climate action goals with validation from the Science Based Targets initiative (S...

October 11, 2021, 6:02 am

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma in australia

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) appro...

October 10, 2021, 5:00 pm

Beigene announces brukinsa® (zanubrutinib) approved for treatment of patients with mantle cell lymphoma

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib)...

October 10, 2021, 5:00 pm

Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...

October 8, 2021, 8:09 pm

Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...

October 8, 2021, 8:09 pm

Enzyvant receives fda approval for rethymic® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissue-based therapy for pediatric congenital athymia

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia...

October 8, 2021, 8:09 pm

Should you buy chemocentryx stock as shares spike 70% on avacopan approval?

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had...

October 8, 2021, 4:30 pm


Search within

Pages Search Results: